Author(s): XU Yimin, LIU Haizhen
Pages: 572-575
Year: 2015 Issue:  6
Journal: International Journal of Immunology
Keyword:  Granulocyte-macrophage colony stimulating factor; Prostatic acid phosphatase; Metastatic castration-resistant prostate cancer;
Abstract: Sipuleucel-T(Provenge(R)) is the first therapeutic autologous DC-based cancer vaccine that improves overall survival approved by the US Food and Drug Administration for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).This review described the process of creating the sipuleucel-T product from the manufacturing and patient aspects.We discussed the recent clinical development of sipuleucel-T immunotherapy for mCRPC and outlined some of the challenges that lay a